A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
186
Participants
Timeline
Start Date
October 31, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Conditions
Relapsed or Refractory Hematologic Malignancies
Interventions
DRUG
QLS2309
initial dose - MTD; QW; intravenous infusion
All Listed Sponsors
lead
Qilu Pharmaceutical Co., Ltd.
INDUSTRY
NCT07173595 - A Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter